<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03597529</url>
  </required_header>
  <id_info>
    <org_study_id>17-22645</org_study_id>
    <nct_id>NCT03597529</nct_id>
  </id_info>
  <brief_title>CHOCOlate MeLatonin for AdolescenT MigrainE</brief_title>
  <acronym>CHOCOLATE</acronym>
  <official_title>CHOCOlate MeLatonin for AdolescenT MigrainE: The CHOCOLATE Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Existing treatments for acute migraine are not effective for all children and adolescents,
      and can cause side effects. We propose a dose-finding study of melatonin for acute migraine
      treatment in children and adolescents to determine the best dose to bring forward in a future
      fully-powered efficacy trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This pilot randomized trial is a dose-finding study to determine which dose of melatonin is
      most effective for treating acute migraine in children and adolescents who have episodic
      migraine. We will identify the most effective dose to pull forward into a future
      fully-powered placebo-controlled efficacy study. If both doses are equally effective, we will
      bring forward the best tolerated dose. If doses are equally well tolerated, we will bring
      forward the lowest effective dose, as this will minimize cost to families should this
      treatment become widely adopted.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 25, 2017</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in VAS score</measure>
    <time_frame>36 months</time_frame>
    <description>change in VAS score</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>melatonin 2mg (equal to or over 40kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>melatonin 2mg (equal to or over 40kg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>melatonin 8mg (equal to or over 40kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>melatonin 8mg (equal to or over 40kg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>melatonin 1mg (under 40kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>melatonin 1mg (under 40kg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>melatonin 4mg (under 40kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>melatonin 4mg (under 40kg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin</intervention_name>
    <description>melatonin</description>
    <arm_group_label>melatonin 1mg (under 40kg)</arm_group_label>
    <arm_group_label>melatonin 2mg (equal to or over 40kg)</arm_group_label>
    <arm_group_label>melatonin 4mg (under 40kg)</arm_group_label>
    <arm_group_label>melatonin 8mg (equal to or over 40kg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Meet ICHD criteria for episodic migraine in children and adolescents, with at least 1
             migraine attack per month on average.

          2. Age 3-17 years

          3. Dissatisfaction with previous acute treatments, for one or more of the following
             reasons: a) One or more previously tried acute medications have not been effective, or
             adequately effective, b) previously tried acute treatments have caused side effects,
             or C) patient/family would prefer a natural supplement for acute treatment over
             medication treatment

          4. If of driving age, teen participant agrees not to drive for at least 8 hours after
             treating with melatonin.

        Exclusion Criteria:

          1. Allergy or intolerance to melatonin, or to chocolate.

          2. Opioid or barbiturate overuse as defined in ICHD

          3. Pregnant/lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Amy A Gelfand, MD</last_name>
    <phone>415-885-7832</phone>
    <email>amy.gelfand@ucsf.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, San Francisco, (UCSF)</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy A. Gelfand, M.D.</last_name>
      <phone>415-885-7832</phone>
      <email>Amy.Gelfand@ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Laura Dapkus, NCPT</last_name>
      <phone>415-860-2202</phone>
      <email>Laura.Dapkus@ucsf.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Victor TW, Hu X, Campbell JC, Buse DC, Lipton RB. Migraine prevalence by age and sex in the United States: a life-span study. Cephalalgia. 2010 Sep;30(9):1065-72. doi: 10.1177/0333102409355601. Epub 2010 Mar 12.</citation>
    <PMID>20713557</PMID>
  </reference>
  <reference>
    <citation>Ambriz-Tututi M, Rocha-Gonz√°lez HI, Cruz SL, Granados-Soto V. Melatonin: a hormone that modulates pain. Life Sci. 2009 Apr 10;84(15-16):489-98. doi: 10.1016/j.lfs.2009.01.024. Epub 2009 Feb 15. Review.</citation>
    <PMID>19223003</PMID>
  </reference>
  <reference>
    <citation>Gitto E, Aversa S, Salpietro CD, Barberi I, Arrigo T, Trimarchi G, Reiter RJ, Pellegrino S. Pain in neonatal intensive care: role of melatonin as an analgesic antioxidant. J Pineal Res. 2012 Apr;52(3):291-5. doi: 10.1111/j.1600-079X.2011.00941.x. Epub 2011 Dec 5.</citation>
    <PMID>22141591</PMID>
  </reference>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>June 26, 2017</study_first_submitted>
  <study_first_submitted_qc>July 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2018</study_first_posted>
  <last_update_submitted>July 13, 2018</last_update_submitted>
  <last_update_submitted_qc>July 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Amy Gelfand</investigator_full_name>
    <investigator_title>Assistant Professor of Neurology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

